Practical Use of Vorasidenib: Patient Selection, Monitoring, and Real-World Considerations

As targeted therapies continue to reshape the management of IDH-mutant glioma, clinicians are increasingly focused on how to effectively integrate these agents into real-world practice. Beyond clinical trial data, considerations such as ease of administration, safety monitoring, and patient counseling play a critical role in ensuring optimal outcomes.

At the 2026 AAN Annual Meeting in Chicago, Katherine B. Peters, MD, PhD, neuro-oncologist at Duke Health and professor of neurology and neurosurgery at the Preston Robert Tisch Brain Tumor Center, spoke with NeurologyLive® about lessons learned from the phase 3 INDIGO trial (NCT04164901) and her clinical experience using vorasidenib. She emphasized the importance of understanding the drug’s mechanism, differentiating it from traditional chemotherapy, and fostering collaboration across specialties to support patient care.

In this final episode, Peters offers practical guidance for clinicians, including how to frame discussions with patients and families, what to monitor during treatment, and how to manage common adverse events such as liver function abnormalities. She also highlights the accessibility of the therapy, its tolerability profile, and the importance of multidisciplinary collaboration in optimizing its use.